IMVT Insider Trading Activity and SEC Form 4 Filings
IMVT insider trading summary
Over the past 12 months, insiders at Immunovant, Inc. (IMVT) reported 56 sales worth $15.5M by 8 insiders and 1 open-market purchase worth $350.0M by 1 insider on SEC Form 4. Net insider buying was $334.5M.
Latest IMVT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 28, 2026 | Tiago Girao | Chief Financial Officer | Sell | $188K (6,606 @ $28.50) |
| Oct 21, 2026 | Jay S Stout | Chief Technology Officer | Sell | $75K (2,595 @ $28.94) |
| Oct 7, 2026 | Jay S Stout | Chief Technology Officer | Sell | $71K (2,213 @ $32.06) |
| Oct 7, 2026 | Jay S Stout | Chief Technology Officer | Sell | $51K (1,596 @ $32.06) |
| Oct 7, 2026 | Melanie Gloria | Chief Operating Officer | Sell | $72K (2,241 @ $32.06) |
| Oct 7, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sell | $43K (1,327 @ $32.06) |
| Oct 2, 2026 | Eric Venker | Chief Executive Officer | Sell | $120K (3,506 @ $34.11) |
| Sep 23, 2026 | Tuyl Christopher Van | Chief Legal Officer | Sell | $103K (2,846 @ $36.36) |
| Aug 28, 2026 | Atul Pande | Director | Sell | $65K (1,500 @ $43.27) |
| Aug 20, 2026 | Melanie Gloria | Chief Operating Officer | Sell | $135K (3,056 @ $44.16) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.